Humacyte Announces Issuance of Three Additional U.S. Patents Covering its Proprietary Universally Implantable Bioengineered Human Tissue Platform

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the issuance of three additional U.S. patents covering its proprietary technology platform.